Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AGEN
CUSIP00847G70
Phone781-674-4400
Debt
Debt-to-Equity Ratio-0.11
Current Ratio2.16
Quick Ratio2.16
Price-To-Earnings
Trailing P/E Ratio-1.72
Forward P/E Ratio-1.44
P/E GrowthN/A
Sales & Book Value
Annual Sales$42.88 million
Price / Sales5.36
Cash FlowN/A
Price / CashN/A
Book Value($0.74) per share
Price / Book-2.99
Profitability
EPS (Most Recent Fiscal Year)($1.23)
Net Income$-120,690,000.00
Net Margins-281.49%
Return on EquityN/A
Return on Assets-98.89%
Miscellaneous
Employees255
Outstanding Shares104,000,000
Market Cap$223.60
Agenus (NASDAQ:AGEN) Frequently Asked Questions
What is Agenus' stock symbol?
Agenus trades on the NASDAQ under the ticker symbol "AGEN."
How were Agenus' earnings last quarter?
Agenus Inc (NASDAQ:AGEN) issued its quarterly earnings data on Monday, May, 7th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.14. View Agenus' Earnings History.
When is Agenus' next earnings date?
What price target have analysts set for AGEN?
1 brokerages have issued 1-year target prices for Agenus' stock. Their predictions range from $7.00 to $7.00. On average, they anticipate Agenus' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 216.7% from the stock's current price. View Analyst Ratings for Agenus.
What is the consensus analysts' recommendation for Agenus?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Agenus' key competitors?
Some companies that are related to Agenus include Autolus Therapeutics (AUTL), Heska (HSKA), La Jolla Pharmaceutical (LJPC), Avrobio (AVRO), Voyager Therapeutics (VYGR), Mesoblast (MESO), BioCryst Pharmaceuticals (BCRX), CASI Pharmaceuticals (CASI), Fate Therapeutics (FATE), Translate Bio (TBIO), Nightstar Therapeutics (NITE), Novavax (NVAX), Surface Oncology (SURF), PDL BioPharma (PDLI) and Vericel (VCEL).
Who are Agenus' key executives?
Agenus' management team includes the folowing people:
- Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 65)
- Ms. Christine M. Klaskin, Principal Accounting Officer (Age 52)
- Dr. Alexander R. Duncan, CTO & Head of Research (Age 56)
- Ms. Karen Higgins Valentine, Chief Legal Officer & Gen. Counsel (Age 46)
- Dr. Robert B. Stein, Sr. R&D Advisor (Age 67)
Has Agenus been receiving favorable news coverage?
Media stories about AGEN stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Agenus earned a news sentiment score of 0.13 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.17 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Agenus?
Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agenus' stock price today?
One share of AGEN stock can currently be purchased for approximately $2.21.
How big of a company is Agenus?
Agenus has a market capitalization of $223.60 million and generates $42.88 million in revenue each year. The biotechnology company earns $-120,690,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Agenus employs 255 workers across the globe.
How can I contact Agenus?
Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]
MarketBeat Community Rating for Agenus (NASDAQ AGEN)
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
